Tilpasset eller modifisert kjemoterapi (doser redusert eller utsatt)

Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F, Tonso A, Alvaro MG, Ciravegna G, Levis A.

Kilde‎: Leuk Res 2011;35(8):991-7.

Arkiv‎: PubMed 21474179

DOI‎: 10.1016/j.leukres.2011.02.021

https://www.ncbi.nlm.nih.gov/pubmed/21474179 (åpner nytt vindu)

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. (åpner nytt vindu)

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR.

Kilde‎: Br J Haematol 2014;165(4):497-503.

Arkiv‎: PubMed 24528179

DOI‎: 10.1111/bjh.12775

https://www.ncbi.nlm.nih.gov/pubmed/24528179 (åpner nytt vindu)

Low-dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses. (åpner nytt vindu)

Dainer PM, Knupp CL, Sartiano GP.

Kilde‎: Am J Hematol 1992;40(2):156-7.

Arkiv‎: PubMed 1585917

https://www.ncbi.nlm.nih.gov/pubmed/1585917 (åpner nytt vindu)

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. (åpner nytt vindu)

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.

Kilde‎: Lancet Oncol 2013;14(6):525-33.

Arkiv‎: PubMed 23578722

DOI‎: 10.1016/S1470-2045(13)70122-0

https://www.ncbi.nlm.nih.gov/pubmed/23578722 (åpner nytt vindu)

Azacitidine and venetoclax in previously untreated acute myeloid leukemia. (åpner nytt vindu)

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW

Kilde‎: N Engl J Med 2020;383(7):617-29.

Arkiv‎: PubMed 32786187

DOI‎: 10.1056/NEJMoa2012971

https://www.ncbi.nlm.nih.gov/pubmed/32786187 (åpner nytt vindu)

Treatment of acute leukaemia in adult Jehovah's Witnesses. (åpner nytt vindu)

El Chaer F, Ballen KK

Kilde‎: Br J Haematol 2020;190(5):696-707.

Arkiv‎: PubMed 31693175

DOI‎: 10.1111/bjh.16284

https://www.ncbi.nlm.nih.gov/pubmed/31693175 (åpner nytt vindu)

Minimally-myelosuppressive asparaginase-containing induction regimen for treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS acute myeloid leukemia. (åpner nytt vindu)

Emadi A, Bade NA, Stevenson B, Singh Z.

Kilde‎: Pharmaceuticals (Basel) 2016;9(1):E12.

Arkiv‎: PubMed 27064021

DOI‎: 10.3390/ph9010012

https://www.ncbi.nlm.nih.gov/pubmed/27064021 (åpner nytt vindu)

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. (åpner nytt vindu)

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T.

Kilde‎: J Clin Oncol 2009;27(28):4733-40.

Arkiv‎: PubMed 19720927

DOI‎: 10.1200/JCO.2008.19.8721

https://www.ncbi.nlm.nih.gov/pubmed/19720927 (åpner nytt vindu)

Successful treatment of a Jehovah's Witness with acute promyelocytic leukemia. (åpner nytt vindu)

Fujita H, Maruta A, Koharazawa H, Hattori M, Tomit N, Kodama F, Mohri H, Okubo T.

Kilde‎: Int J Hematol 1997;65(4):415-6.

Arkiv‎: PubMed 9195782

https://www.ncbi.nlm.nih.gov/pubmed/9195782 (åpner nytt vindu)

Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. (åpner nytt vindu)

Garelius H, Grund S, Stockelberg D.

Kilde‎: Clin Case Rep 2015;3(5):287-90.

Arkiv‎: PubMed 25984306

https://www.ncbi.nlm.nih.gov/pubmed/25984306 (åpner nytt vindu)

Immediate or delayed therapy with 2-CdA for hairy cell leukemia in Jehova's Witness? (åpner nytt vindu)

Juliusson G.

Kilde‎: Am J Hematol 1996;53(1):49.

Arkiv‎: PubMed 8813099

DOI‎: 10.1002/(SICI)1096-8652(199609)53:1<49::AID-AJH12>3.0.CO;2-Z

https://www.ncbi.nlm.nih.gov/pubmed/8813099 (åpner nytt vindu)

Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. (åpner nytt vindu)

Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, Pruneri G, Calabrese L, Cocquio A, Martinelli G.

Kilde‎: Eur J Haematol 2004;72(4):264-7.

Arkiv‎: PubMed 15089764

DOI‎: 10.1111/j.0902-4441.2003.00211.x

https://www.ncbi.nlm.nih.gov/pubmed/15089764 (åpner nytt vindu)

Successful treatment of acute promyelocytic leukemia in a pregnant Jehovah's Witness with all-trans retinoic acid, rhG-CSF, and erythropoietin. (åpner nytt vindu)

Lin CP, Huang MJ, Liu HJ, Chang IY, Tsai CH.

Kilde‎: Am J Hematol 1996;51(3):251-2.

Arkiv‎: PubMed 8619417

DOI‎: 10.1002/(SICI)1096-8652(199603)51:3<251::AID-AJH20>3.0.CO;2-I

https://www.ncbi.nlm.nih.gov/pubmed/8619417 (åpner nytt vindu)

Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. (åpner nytt vindu)

Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, Huang J, Jin J.

Kilde‎: Hematol Oncol 2014;32(1):40-6.

Arkiv‎: PubMed 23963734

DOI‎: 10.1002/hon.2076

https://www.ncbi.nlm.nih.gov/pubmed/23963734 (åpner nytt vindu)

Cytarabine dose for acute myeloid leukemia. (åpner nytt vindu)

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.

Kilde‎: N Engl J Med 2011;364(11):1027-36.

Arkiv‎: PubMed 21410371

DOI‎: 10.1056/NEJMoa1010222

https://www.ncbi.nlm.nih.gov/pubmed/21410371 (åpner nytt vindu)

Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. (åpner nytt vindu)

Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L, Pricolo G.

Kilde‎: Bone Marrow Transplant 2003;32(4):433-6.

Arkiv‎: PubMed 12900781

DOI‎: 10.1038/sj.bmt.1704179

https://www.ncbi.nlm.nih.gov/pubmed/12900781 (åpner nytt vindu)

Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. (åpner nytt vindu)

Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, de Botton S, Döhner H

Kilde‎: N Engl J Med. 2022;386(16):1519-31.

Arkiv‎: PubMed 35443108

DOI‎: 10.1056/NEJMoa2117344

https://pubmed.ncbi.nlm.nih.gov/35443108/ (åpner nytt vindu)

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. (åpner nytt vindu)

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R.

Kilde‎: Gynecol Oncol 2012;124(2):221-4.

Arkiv‎: PubMed 22055764

DOI‎: 10.1016/j.ygyno.2011.10.003

https://www.ncbi.nlm.nih.gov/pubmed/22055764 (åpner nytt vindu)

The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products. (åpner nytt vindu)

Nguyen N, Madarang E, Alencar A, Watts J, Bradley T

Kilde‎: Leuk Res Rep. 2022 25;18:100355.

Arkiv‎: PubMed 36338830

DOI‎: 10.1016/j.lrr.2022.100355

https://pubmed.ncbi.nlm.nih.gov/36338830/ (åpner nytt vindu)

Developing a blood conservation care plan for Jehovah's Witness patients with malignant disease. (åpner nytt vindu)

Norfolk DR, Wade P, Carter R.

Kilde‎: Presented at the British Society for Haematology 47th Annual Scientific Meeting, Bournemouth [UK] April 2007.

https://www.transfusionguidelines.org/document-library/documents/developing-a-blood-conservation-care-plan-for-jehovah-s-witness-patients-with-malignant-disease/download-file/bbt-JW-Care-Plan-Malignant-Disease-2012.pdf (åpner nytt vindu)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (åpner nytt vindu)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Kilde‎: Leuk Lymphoma. 2019;60(9):2324-7.

Arkiv‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (åpner nytt vindu)

Hematopoietic growth factors: personalization of risks and benefits. (åpner nytt vindu)

Puhalla S, Bhattacharya S, Davidson NE.

Kilde‎: Mol Oncol 2012;6(2):237-41.

Arkiv‎: PubMed 22497867

DOI‎: 10.1016/j.molonc.2012.03.001

https://www.ncbi.nlm.nih.gov/pubmed/22497867 (åpner nytt vindu)

Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. (åpner nytt vindu)

Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR

Kilde‎: Leuk Lymphoma 2021;62(6):1497-501.

Arkiv‎: PubMed 33535838

DOI‎: 10.1080/10428194.2021.1876868

https://www.ncbi.nlm.nih.gov/pubmed/33535838 (åpner nytt vindu)

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. (åpner nytt vindu)

Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM

Kilde‎: Blood 2020;135(7):463-71.

Arkiv‎: PubMed 31841594

DOI‎: 10.1182/blood.2019002140

https://www.ncbi.nlm.nih.gov/pubmed/31841594 (åpner nytt vindu)

Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. (åpner nytt vindu)

Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, Tarín-Arzaga LD, Manzano C.

Kilde‎: Bone Marrow Transplant 2005;36(8):715-20.

Arkiv‎: PubMed 16113672

DOI‎: 10.1038/sj.bmt.1705126

https://www.ncbi.nlm.nih.gov/pubmed/16113672 (åpner nytt vindu)

A Mexican way to cope with stem cell grafting. (åpner nytt vindu)

Ruiz-Delgado GJ, Ruiz-Argüelles GJ.

Kilde‎: Hematology 2012;17 Suppl 1:S195-7.

Arkiv‎: PubMed 22507819

DOI‎: 10.1179/102453312X13336169157130

https://www.ncbi.nlm.nih.gov/pubmed/22507819 (åpner nytt vindu)

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (åpner nytt vindu)

Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F.

Kilde‎: Blood 2009;113(9):1875-91.

Arkiv‎: PubMed 18812465

DOI‎: 10.1182/blood-2008-04-150250

https://www.ncbi.nlm.nih.gov/pubmed/18812465 (åpner nytt vindu)

SCT in Jehovah's Witnesses: the bloodless transplant. (åpner nytt vindu)

Sloan JM, Ballen K.

Kilde‎: Bone Marrow Transplant 2008;41(10):837-44.

Arkiv‎: PubMed 18246110

DOI‎: 10.1038/bmt.2008.5

https://www.ncbi.nlm.nih.gov/pubmed/18246110 (åpner nytt vindu)

Treatment of acute myelogenous leukemia with outpatient azacitidine. (åpner nytt vindu)

Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J.

Kilde‎: Cancer 2006;107(8):1839-43.

Arkiv‎: PubMed 16967444

DOI‎: 10.1002/cncr.22204

https://www.ncbi.nlm.nih.gov/pubmed/16967444 (åpner nytt vindu)

Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's Witness. (åpner nytt vindu)

van Akkooi AC, Golab-Schwarz HD, Eggermont AM, van Geel AN.

Kilde‎: Eur J Cardiothorac Surg 2006;30(2):408-10.

Arkiv‎: PubMed 16829108

DOI‎: 10.1016/j.ejcts.2006.04.020

https://www.ncbi.nlm.nih.gov/pubmed/16829108 (åpner nytt vindu)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. (åpner nytt vindu)

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

Kilde‎: Onco Targets Ther 2013;7:13-21.

Arkiv‎: PubMed 24368888

DOI‎: 10.2147/OTT.S53348

https://www.ncbi.nlm.nih.gov/pubmed/24368888 (åpner nytt vindu)

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. (åpner nytt vindu)

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.

Kilde‎: J Clin Oncol 2007;25(30):4722-9.

Arkiv‎: PubMed 17947719

DOI‎: 10.1200/JCO.2007.12.2440

https://www.ncbi.nlm.nih.gov/pubmed/17947719 (åpner nytt vindu)

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. (åpner nytt vindu)

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P

Kilde‎: Blood 2020;135(24):2137-45.

Arkiv‎: PubMed 32219442

DOI‎: 10.1182/blood.2020004856

https://www.ncbi.nlm.nih.gov/pubmed/32219442 (åpner nytt vindu)